Cited 10 times in
Comparison of the intraocular pressure-lowering effect and safety of brimonidine/timolol fixed combination and 0.5% timolol in normal-tension glaucoma patients.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김찬윤 | - |
dc.date.accessioned | 2017-02-27T08:06:38Z | - |
dc.date.available | 2017-02-27T08:06:38Z | - |
dc.date.issued | 2016 | - |
dc.identifier.issn | 0021-5155 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/147084 | - |
dc.description.abstract | PURPOSE: To compare the therapeutic efficacy and safety of brimonidine/timolol fixed-combination (BTFC) and 0.5% timolol ophthalmic solution in normal-tension glaucoma (NTG) patients. METHODS: This was a multi-institution, randomized, active-controlled, open-label, parallel-group study. After a full ophthalmic and glaucoma examination, a total of 110 NTG patients--55 undergoing therapy with BTFC and 55 0.5%, with timolol--participated in this study. Among them, 1 failed to meet the inclusion/exclusion criteria, 10 revoked their consent to participate in the study, 3 had adverse reactions, and 1 had a drug adherence rate of less than 70%. Ultimately, a total of 95 patients--48 in the BTFC group and 47 in the 0.5% timolol group--completed the study. The study visits took place at baseline and at 4 and 12 weeks. Diurnal IOP was measured at 9 a.m., 11 a.m., and 5 p.m. during the baseline visit and the visit at 12 weeks after eye-drop instillation. At each follow-up visit, compliance was assessed. Throughout the study, all adverse events were recorded and monitored by the investigators. RESULTS: The average difference in IOP change measured at 11 a.m. 12 weeks after administration between the two groups was 2.10 ± 2.59 mmHg. The BTFC group had a better IOP-lowering effect at all time points than did the 0.5% timolol group. The ratio of patients whose average IOP had decreased by >20% after 4 and 12 weeks was 50 and 56% in the BTFC group, respectively, whereas it was 29.41 and 23.53% in the 0.5% timolol group, respectively (p = 0.034, <0.001). CONCLUSIONS: BTFC has a superior IOP-lowering effect than 0.5% timolol in NTG patients. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.format.extent | 20~26 | - |
dc.language | English | - |
dc.publisher | Springer Tokyo | - |
dc.relation.isPartOf | JAPANESE JOURNAL OF OPHTHALMOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Administration, Topical | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antihypertensive Agents/adverse effects | - |
dc.subject.MESH | Antihypertensive Agents/therapeutic use* | - |
dc.subject.MESH | Brimonidine Tartrate/adverse effects | - |
dc.subject.MESH | Brimonidine Tartrate/therapeutic use* | - |
dc.subject.MESH | Corneal Pachymetry | - |
dc.subject.MESH | Drug Combinations | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Intraocular Pressure/drug effects* | - |
dc.subject.MESH | Low Tension Glaucoma/drug therapy* | - |
dc.subject.MESH | Low Tension Glaucoma/physiopathology | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Ophthalmic Solutions | - |
dc.subject.MESH | Prospective Studies | - |
dc.subject.MESH | Timolol/adverse effects | - |
dc.subject.MESH | Timolol/therapeutic use* | - |
dc.subject.MESH | Tonometry, Ocular | - |
dc.title | Comparison of the intraocular pressure-lowering effect and safety of brimonidine/timolol fixed combination and 0.5% timolol in normal-tension glaucoma patients. | - |
dc.type | Article | - |
dc.publisher.location | Japan | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Ophthalmology | - |
dc.contributor.googleauthor | Joon Mo Kim | - |
dc.contributor.googleauthor | Tae-Woo Kim | - |
dc.contributor.googleauthor | Chan Yun Kim | - |
dc.contributor.googleauthor | Hwang Ki Kim | - |
dc.contributor.googleauthor | Ki Ho Park | - |
dc.identifier.doi | 10.1007/s10384-015-0420-2 | - |
dc.contributor.localId | A01035 | - |
dc.relation.journalcode | J01209 | - |
dc.identifier.eissn | 1613-2246 | - |
dc.identifier.pmid | 26578422 | - |
dc.identifier.url | http://link.springer.com/article/10.1007/s10384-015-0420-2 | - |
dc.subject.keyword | 0.5 % timolol | - |
dc.subject.keyword | Brimonidine/timolol fixed combination | - |
dc.subject.keyword | Drug efficacy | - |
dc.subject.keyword | Normal-tension glaucoma | - |
dc.contributor.alternativeName | Kim, Chan Yun | - |
dc.contributor.affiliatedAuthor | Kim, Chan Yun | - |
dc.citation.volume | 60 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 20 | - |
dc.citation.endPage | 26 | - |
dc.identifier.bibliographicCitation | JAPANESE JOURNAL OF OPHTHALMOLOGY, Vol.60(1) : 20-26, 2016 | - |
dc.date.modified | 2017-02-24 | - |
dc.identifier.rimsid | 47116 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.